Trius Therapeutics, Inc. (NASDAQ:TSRX): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Sell on July 1, 2013. The stock’s 52-week high is $9.87, and its 52-week low is $4.41.
While the Mad Money host did caution using limit orders to purchase this stock, after speaking with chief executive Cramer seemed convinced of the stock’s merits. Chief executive Jeff Stein pointed to the GAIN Act passed last year by Congress as a tool which has allowed them to partner with the Food and Drug Administration to bring their products to market quickly. The company is working on drugs that tackle infections untreatable by current antibiotics as well as getting patients better faster so they can get out of the hospital faster to lower exposure risks.